SAADIA GHAZAL: Open Payments
NPI 1922735570 · MILWAUKEE, WI. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$981 in 40 payments from 13 companies in 2025. Trend: 2023 $594 · 2024 $1,244 · 2025 $981
Food & beverage: $981
| Company | Payments | Amount |
|---|---|---|
| ABBVIE INC. | 9 | $221 |
| AstraZeneca Pharmaceuticals LP | 7 | $182 |
| Otsuka America Pharmaceutical, Inc. | 5 | $117 |
| Novo Nordisk Inc | 4 | $99 |
| Bayer Healthcare Pharmaceuticals Inc. | 4 | $87 |
| Aimmune Therapeutics, Inc. | 3 | $67 |
| PFIZER INC. | 2 | $49 |
| Phathom Pharmaceuticals, Inc. | 1 | $29 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 1 | $29 |
| Astellas Pharma US Inc | 1 | $27 |
Products named: AIRSUPRA, REXULTI, Kerendia, Wegovy, LINZESS, QULIPTA, ZENPEP, UBRELVY.
Industry payments across WI — which companies pay providers there.
